Stockreport

Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety tox [Read more]